Literature DB >> 21252003

Clinical profile and surgical outcome for pulmonary aspergilloma: nine year retrospective observational study in a tertiary care hospital.

Mubashir Ali Khan1, Abdul Majeed Dar, Nadeem Ulnazeer Kawoosa, Abdul Gani Ahangar, Ghulam Nabi Lone, Gulnaz Bashir, Mohammad Akbar Bhat, Shyam Singh.   

Abstract

BACKGROUND: The indications and the outcome of surgery for pulmonary aspergilloma remain highly controversial. This retrospective observational study was conducted to study the clinical profile, indications, post-operative complications and long term outcome of patients having pulmonary aspergilloma.
METHODS: From January 2000 to October 2008, 52 patients underwent surgery for pulmonary aspergilloma at our tertiary care institute.
RESULTS: The group consisted of 32 males and 20 females with a mean age of 39.3 ± 11.2 years. The most common indication for surgery was hemoptysis (96.15%). The underlying lung diseases were tuberculosis (75%), bronchiectasis (5.76%), and lung abscess (5.76%). In one patient (2%), concomitant ruptured lung hydatid cyst and an aspergilloma was present. The procedures performed were lobectomy (n = 43), bilobectomy (n = 3). pneumonectomy (n = 3), segmental resection (n = 3). The post-operative mortality was 1.92% (one patient). Overall complications occurred in 12 (23.07%) patients. The complications included prolonged air leak (n = 6), bleeding (n = 3), empyema (n = 1), repeated pneumothorax (n = 1), and wound dehiscence (n = 1). The mean follow-up period was 38 ± 18.6 months. There was no recurrence of disease or hemoptysis.
CONCLUSION: Pulmonary aspergilloma is common in developing countries like India in which there is high prevalence of pulmonary tuberculosis. Surgical resection of pulmonary aspergilloma is effective in preventing recurrence of symptoms including hemoptysis. We recommend early surgical resection of symptomatic aspergilloma with reasonable complications. Pre-operative preparation of the patients, meticulous surgical technique and post-operative chest physiotherapy reduces the rate of complications. Complications may still occur and are largely related to the underlying lung pathology; however, the long term outcome is good.
Copyright © 2011 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21252003     DOI: 10.1016/j.ijsu.2011.01.002

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  5 in total

1.  Feasibility of surgery for pulmonary aspergilloma: analysis of the operative modes.

Authors:  Kazuyuki Komori; Aritoshi Hattori; Takeshi Matsunaga; Kazuya Takamochi; Shiaki Oh; Kenji Suzuki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-03-14

2.  Survival following lung resection in immunocompromised patients with pulmonary invasive fungal infection.

Authors:  Geena X Wu; Marine Khojabekyan; Jami Wang; Bernard R Tegtmeier; Margaret R O'Donnell; Jae Y Kim; Frederic W Grannis; Dan J Raz
Journal:  Eur J Cardiothorac Surg       Date:  2015-03-01       Impact factor: 4.191

3.  Risk factors of severe hemoptysis in patients with fungus ball.

Authors:  Tae Hoon Kim; Hyun Jung Koo; Chae-Man Lim; Sang-Bum Hong; Jin Won Huh; Kyung Wook Jo; Tae Sun Shim; Woo Sung Kim; Younsuck Koh
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

4.  Hemoptysis from complex pulmonary aspergilloma treated by cavernostomy and thoracoplasty.

Authors:  Nguyen Truong Giang; Le Tien Dung; Nguyen Thanh Hien; Truong Thanh Thiet; Phan Sy Hiep; Nguyen The Vu; Dinh Cong Pho; Nguyen Van Nam; Pham Ngoc Hung
Journal:  BMC Surg       Date:  2019-12-05       Impact factor: 2.102

5.  Plombage for Hemoptysis Control in Pulmonary Aspergilloma: Safety and Effectiveness of Forgettable Surgery in High-Risk Patients.

Authors:  Nguyen Truong Giang; Le Tien Dung; Nguyen Thanh Hien; Truong Thanh Thiet; Phan Sy Hiep; Dinh Cong Pho; Pham Ngoc Hung
Journal:  Ann Thorac Cardiovasc Surg       Date:  2021-01-06       Impact factor: 1.520

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.